metformin has been researched along with Scleroderma, Systemic in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tofacitinib is a pan-JAK inhibitör." | 5.72 | Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis. ( Akar, ZA; Akkoc, RF; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2022) |
| "Although the pathogenesis of systemic sclerosis is not exactly known, it is thought that immune activation has prominent roles in pathogenesis." | 5.62 | Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis. ( Akar, ZA; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2021) |
| "Tofacitinib is a pan-JAK inhibitör." | 1.72 | Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis. ( Akar, ZA; Akkoc, RF; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2022) |
| "Although the pathogenesis of systemic sclerosis is not exactly known, it is thought that immune activation has prominent roles in pathogenesis." | 1.62 | Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis. ( Akar, ZA; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Karatas, A | 2 |
| Oz, B | 2 |
| Celik, C | 2 |
| Akar, ZA | 2 |
| Akkoc, RF | 1 |
| Etem, EO | 2 |
| Dagli, AF | 2 |
| Koca, SS | 2 |
| Ursini, F | 1 |
| Grembiale, RD | 1 |
| D'Antona, L | 1 |
| Gallo, E | 1 |
| D'Angelo, S | 1 |
| Citraro, R | 1 |
| Visca, P | 1 |
| Olivieri, I | 1 |
| De Sarro, G | 1 |
| Perrotti, N | 1 |
| Russo, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for metformin and Scleroderma, Systemic
| Article | Year |
|---|---|
Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis.
Topics: Animals; Drug Therapy, Combination; Female; Fibrosis; Metformin; Mice; Mice, Inbred BALB C; Piperidi | 2022 |
Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bleomycin; Collagen; Disease Models, Animal; Female; Fib | 2021 |
Oral Metformin Ameliorates Bleomycin-Induced Skin Fibrosis.
Topics: Administration, Oral; Animals; Bleomycin; Disease Models, Animal; Female; Fibrosis; Humans; Metformi | 2016 |